Combined therapy with pegylated IFN-alpha and ribavirin enables to achieve EVR in 8/10 treated children with CHC infected with genotype 1. Lower ALT activity, lower HCV viral load and small progression of fibrosis in the histopathological evaluation have positive influence on EVR.